MedTrace Logo

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

NCT02181738 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2023-11-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.

Conditions

  • Hodgkin Disease

Interventions

DRUG

Nivolumab

Specified dose on specified days

DRUG

Doxorubicin

Specified dose on specified days

DRUG

Vinblastine

Specified dose on specified days

DRUG

Dacarbazine

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-12
Primary Completion
2017-08-31
Completion
2022-12-27

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • Czechia
  • Germany
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02181738 on ClinicalTrials.gov